How did OSRH's recent EPS compare to expectations?
The most recent EPS for OSR Holdings Inc is $, expectations of $-0.29.
How did OSR Holdings Inc OSRH's revenue perform in the last quarter?
OSR Holdings Inc revenue for the last quarter is $
What is the revenue estimate for OSR Holdings Inc?
According to 3 of Wall street analyst, the revenue estimate of OSR Holdings Inc range from $816.9K to $762.44K
What's the earning quality score for OSR Holdings Inc?
OSR Holdings Inc has a earning quality score of A-/60.10668. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does OSR Holdings Inc report earnings?
OSR Holdings Inc next earnings report is expected in 2026-08-16
What are OSR Holdings Inc's expected earnings?
OSR Holdings Inc expected earnings is $793.56K, according to wall-street analysts.
Did OSR Holdings Inc beat earnings expectations?
OSR Holdings Inc recent earnings of $ expectations.
Key Stats
Prev.Close
$0.3692
Open
$0.369
Day's Range
$0.36 - $0.3758
52 week range
$0.36 - $1.79
Volume
--
Avg.Volume
4.6M
Dividend yield
--
EPS (TTM)
-0.36
Market Cap
$12.6M
What is OSRH?
OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.